Company / Working Capital
Apogee Therapeutics, Inc. Working Capital History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$501.2M
FY2024
5-year range
$142.1M / $501.2M
FY2022-FY2024
Trend
+32.6%
vs FY2023
Sector context
#93 of 213
Health Care
What the data says
At $501M, Apogee Therapeutics, Inc.'s working capital ranks #93 of 213 in the Health Care sector. Improved from $142M to $501M over the past 2 years.
Based on SEC 10-K filings.
$501M in FY2024.
Improved from $142M to $501M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#93 of 213 in Health CareTop 44% of 213This company $501.2M Sector average $934.6M
▼
-46.4% below sector average
Key checks
Key Insights
- In FY2024, working capital increased 32.6% year-over-year.
- Ranks #93 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $501.2M | +32.6% |
| FY2023 | $377.9M | +166.0% |
| FY2022 | $142.1M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026